For decades, Alzheimer’s research has operated like a cop show with only two suspects: beta-amyloid plaques outside neurons and tau tangles inside them. Target one, target the other, repeat. Billions spent. Modest results. Now a University of Minnesota team has identified a third structural lesion that nobody was looking for — and it may show up before the usual suspects even arrive at the scene.
Recently published in Nature Neuroscience, the study describes “mitochondrial plaques” (MPs): large, dense accumulations of damaged mitochondria — the tiny power plants that keep your neurons running — clustered inside brain cells. Found in Alzheimer’s model mice and confirmed in post-mortem human brain tissue, these structures were completely absent in healthy controls.
A Garbage Strike Inside Your Brain Cells
Mitochondrial plaques form when neurons can’t take out their own trash.
Classic amyloid plaques sit outside neurons. MPs form inside them — within neuronal processes in the cortex and hippocampus. Think of it like a city sanitation strike during a heatwave: the garbage is broken-down cellular machinery, and nobody’s coming to collect it.
Two systems fail in tandem. Mitochondria accumulate abnormally. Then mitophagy — the cellular process that normally degrades worn-out mitochondria — collapses. Lysosomal function, the cell’s broader waste-disposal system, breaks down alongside it. The result is APP-rich cellular debris piling into plaque-like structures within the neuron itself.
Key findings from the research:
- MPs were identified using a mitophagy reporter tool (mt-Keima) in APP/PSEN1 mice and confirmed in post-mortem human AD hippocampal tissue
- Completely absent in age-matched healthy controls
- Can appear before extensive amyloid deposition begins
- Frequently merge with amyloid plaques later, forming “mixed plaques”
- Contain high concentrations of amyloid precursor protein (APP), linking mitochondrial damage directly to amyloid production
“Unlike the amyloid plaques found outside brain cells, these plaques appear to directly affect neurons, which make them a potential new target for Alzheimer’s disease treatments,” said first author Xiuli Dan at the University of Minnesota.
Why This Matters Beyond Another Lab Finding
MPs could open an earlier diagnostic window — and a new therapeutic front that existing treatments don’t touch.
MPs sit at the intersection of three targetable failures: impaired mitophagy, lysosomal dysfunction, and intracellular APP accumulation. The research team plans to screen small molecules that either prevent MP formation or promote their clearance. The work was funded by NIH/NIA grants and a National Academy of Medicine Healthy Longevity Catalyst Award.
“By understanding how these plaques form and contribute to disease progression, we may be able to develop new strategies to slow or even prevent Alzheimer’s disease,” said Paul Robbins, PhD, at the University of Minnesota.
Some researchers caution that MPs will need longitudinal human data before reshaping diagnostic criteria — and that amyloid and tau remain the defining hallmarks of AD neuropathology. Fair enough. But the old chicken-and-egg debate — does amyloid wreck mitochondria, or do mitochondria seed amyloid — may itself be the wrong question. Both form discrete lesions. Both make each other worse. Like doom-scrolling and insomnia, they sustain a vicious cycle neither can escape alone.
If MPs prove to be detectable before standard amyloid biomarkers, you’re looking at a potential earlier diagnostic window — one that could widen the therapeutic runway considerably. Alzheimer’s research spent decades scanning outside neurons for answers. The most damning evidence may have been quietly disintegrating within them all along.
